Treatment of acute hepatitis C in breast cancer patient: a case report

Oncologists worldwide are often dealing with hepatitis C virus positive breast cancer patients, questioning adequate chemotherapy protocol, reduction of doses, delays, or even interruptions of treatment. We present a case of a woman in stage IIIB breast cancer, who after the completion of neoadjuvan...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2014-06, Vol.26 (3), p.180-183
Main Authors: MATOVINA-BRKO, Gorana, RUZIC, Maja, FABRI, Milotka, POPOVIC, Lazar, KOLAROV-BJELOBRK, Ivana, TRIFUNOVIC, Jasna, PETKOVIC, Danijela
Format: Article
Language:English
Subjects:
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antiviral Agents - administration & dosage
Biological and medical sciences
Breast cancer
Breast Neoplasms - complications
Breast Neoplasms - drug therapy
Carcinoma, Ductal, Breast - complications
Carcinoma, Ductal, Breast - drug therapy
Female
Gynecology. Andrology. Obstetrics
Hepatitis C - complications
Hepatitis C - drug therapy
Hepatitis C virus
Human viral diseases
Humans
Infectious diseases
Interferons - administration & dosage
Mammary gland diseases
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Pharmacology. Drug treatments
Tumors
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncologists worldwide are often dealing with hepatitis C virus positive breast cancer patients, questioning adequate chemotherapy protocol, reduction of doses, delays, or even interruptions of treatment. We present a case of a woman in stage IIIB breast cancer, who after the completion of neoadjuvant treatment developed significant increase in liver enzymes and was diagnosed positive for HCV. She was treated with interferon and after the resolving of acute liver disease continued concomitant treatment with interferon, ribavirin, docetaxel, and trastuzumab. Grade 4 neutropenia and grade 3 hepatotoxicity occurred after the third cycle of chemo and 5 months of antiviral therapy. Interferon and chemotherapy were postponed for 1 week. There are no sufficient data in order to recommend the concomitant antiviral and antineoplastic therapy. Hepatitis C virus and antiviral therapy may increase the toxicities of antineoplastic treatment. However, when lifesaving oncologic treatment is necessary, concomitant antiviral therapy can be administered with more intensive follow up.
ISSN:1120-009X
1973-9478
DOI:10.1179/1973947813Y.0000000129